Herszényi László, Pregun István, Tulassay Zsolt
2nd Department of Medicine, Semmelweis University, and Clinical Gastroenterology Research Unit, Hungarian Academy of Sciences, Budapest, Hungary.
Dig Dis. 2009;27(1):24-30. doi: 10.1159/000210100. Epub 2009 May 8.
Barrett's esophagus (BE) is the precursor lesion of esophageal adenocarcinoma, a malignancy with increasing incidence in Western countries. Malignant transformation of Barrett's metaplasia is a multistep process in which intestinal metaplasia progresses through low-grade and high-grade dysplasia into eventually invasive cancer. Several risk factors for the development of BE have been identified. The degree of dysplasia is currently used as the most important marker of risk progression. The exact incidence of progression from BE to esophageal adenocarcinoma is unknown. Endoscopic surveillance and follow-up are advised in order to detect adenocarcinoma and its precursor precancerous lesions at an early and curable stage, although there has been much debate on this topic. New endoscopic imaging techniques may improve the detection of relevant precancerous lesions and early neoplasia. The use of biomarkers may enable identification of patients at risk for malignant progression.
巴雷特食管(BE)是食管腺癌的前驱病变,食管腺癌在西方国家的发病率呈上升趋势。巴雷特化生的恶性转化是一个多步骤过程,其中肠化生会经过低级别和高级别发育异常最终发展为浸润性癌。已确定了BE发生的几个风险因素。发育异常程度目前被用作风险进展的最重要标志物。BE进展为食管腺癌的确切发生率尚不清楚。建议进行内镜监测和随访,以便在可治愈的早期阶段检测到腺癌及其癌前病变,尽管关于这一话题存在诸多争议。新的内镜成像技术可能会提高相关癌前病变和早期肿瘤的检测率。生物标志物的使用可能有助于识别有恶性进展风险的患者。